Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm. We herein describe the case of a 41-year-old woman who was admitted with nephrotic syndrome (NS) and severe neutrophilia and underwent a splenectomy due to splenomegaly. Peripheral blood tests revealed a Janus kinase 2 (JAK2) V617F mutation without the Philadelphia chromosome, BCR-ABL fusion transcripts, or FIP1 L1-platelet-derived growth factor (PDGF)a. A kidney biopsy showed focal segmental glomerulosclerosis (FSGS) with interstitial neutrophil infiltration and with a JAK2 V617F mutation. Hydroxyurea was initiated for first three months, followed by hydroxyurea plus interferon, and a subsequent improvement in leukocytosis and completely remission of FSGS-NS was immediately noted. This is the first case reported in which NS was related to CNL.
Introduction
Chronic neutrophilic leukemia (CNL) is a rare BCR/ABLnegative myeloproliferative neoplasm (MPN) characterized by persistent neutrophilia and splenomegaly (1, 2) . Most patients with CNL have a poor prognosis, with a median survival of less than three years (3) . Few therapies are available for treatment, and the disease may become refractory to treatment. Most therapeutic options for CNL, namely, hydroxyurea (HU), busulfan, and 6-thioguanine, at best only stabilize the neutrophilia. We herein describe a unique case of nephritic syndrome with CNL.
Case Report
A 41-year-old woman presented to our hospital with the chief complaint of experiencing face edema for approximately one month 12 months ago. During the review of systems, the patient denied joint swelling and pain, rash, nocturia, fever, or any particular exacerbating or remitting factors that would explain her current condition. A local hospital examination showed serum albumin, 25.6 g/L and urine protein+++. The physical exam revealed an 18-cm-long scar on her left upper quadrant.
Previous evidence of leukocytosis had been documented at a local hospital 18 months before: white blood cell (WBC) count, 21.1×10 9 /L; neutrophil (N), 90.3%; hemoglobin (HB), 158 g/L; and platelet (PLT), 356×10 9 /L. She showed evidence of accompanying splenomegaly and hepatomegaly, and further examination revealed lymph node enlargement. The patient was placed on HU for presumed acute leukemia for one month. However, a bone marrow biopsy performed at the time did not show evidence of leukemia. The patient did not demonstrate any major or minor BCR-ABL fusion transcripts. HU was not given, and she was subsequently placed on Chinese herb therapy. The patient had undergone a splenectomy because of splenomegaly at a local hospital 16 months prior and received a diagnosis of spleen infarction and extramedullary hematopoiesis (Figure A) . Three months before admission, she showed evidence of thrombocytosis and leukocytosis (WBC, 61. PLT, 733×10 9 /L). Several laboratory tests were ordered during the initial work-up at our facility ( Table 1 ) that revealed the following: WBC count, 115×10 9 /L; N, 88%; PLT, 1,026×10 9 /L; HB, 142 g/L. No circulating myeloblasts or other immature leukocytes were noted. The patient's serum albumin was 16.6 g/L, and her 24-hour urine protein was 11.7 g. The pathologist's interpretation of the peripheral smear was leukocytosis consisting nearly entirely of mature granulocytes and band forms with no dysplastic changes noted in any lineage. Blood and urine cultures collected on admission were both negative after seven days of growth. Imaging studies, including chest X-rays and abdomen computed tomography (CT), showed no evidence of either an infectious infiltrate or a malignant process.
Her bone marrow smear ( Figure B ) and biopsy (Figure C) showed increased blasts or dysplasia; there was evidence of leukocytosis consisting predominantly of mature neutrophils with Döhle bodies and prominent toxic granules but no obvious megakaryocyte proliferation. Immuno-electrophoresis did not detect monoclonal immunoglobulins. Infectious diseases were excluded by whole-body CT and blood, urine, and sputum cultures. The Philadelphia (Ph) chromosome was not found. Reverse transcription polymerase chain reaction (RT-PCR) did not reveal any major or minor BCR-ABL fusion transcripts or FIP1 L1-PDGFa. The Janus kinase 2 (JAK2) V617F mutation was detected in the patient's peripheral blood by allele-specific PCR analysis. Utilizing the rigorous criteria defined by the World Health Organization (WHO), the patient met all criteria for a diagnosis of CNL. The final diagnosis was chronic neutrophilic leukemia and nephrotic syndrome. She underwent a kidney biopsy, which showed glomeruli with characteristic tip lesions and adhesion of the tuft to Bowman's capsule, and tip variant type of focal segmental glomerulosclerosis (FSGS) was diagnosed with obvious interstitial neutrophil infiltration ( Figure D-F) and a JAK2 V617F mutation. Based on the firm establishment of CNL and her kidney tissue positivity for a JAK2 V617F mutation, nephrotic syndrome (NS) related to CNL was diagnosed, HU was reinitiated, and an improvement in leukocytosis was immediately noted. The patient's WBC count corrected to 5.8×10 9 /L within half month after restarting this medication. After three months of treatment with HU, the patient was given 500 million units of recombinant human interferon α2b once a day combined with HU. After her WBC recovered, her 24-hour urine protein decreased to 0.25 g, and her serum albumin returned to 43.9 g/L in January 2013. To date, she is maintained on chronic therapy with HU and interferon with adequate suppression of her leukocyte count and urine protein levels ( Table 2) .
Discussion
CNL is a rare MPN and it should be a diagnosis of exclusion. Although CNL was first described in 1920 by Tuohy, little is known about its pathogenesis or optimal treatment (3). According to the WHO 2008 CNL definition, CNL is characterized by sustained peripheral blood neutrophilia, bone marrow hypercellularity due to neutrophilic granulocyte proliferation, and hepatosplenomegaly (4). It can only be confidently diagnosed following careful exclusion of the presence of the BCR-ABL gene transcript associated with chronic myeloid leukemia and other diseases that might cause a leukemoid reaction (e.g., occult malignancy, ongoing infections and other inflammatory conditions). In our patient, there was no evidence of infection, and underlying malignancy was also excluded by the ab-sence of signs and symptoms and signs and her normal radiological findings. Chronic myeloid leukemia had to be excluded in our patient, especially given the presence of hepatosplenomegaly, by negative findings for the BCR-ABL fusion gene. Myelodysplastic syndrome can sometimes be associated with neutrophilia, although one would expect dysplastic features in other cell lines and abnormal cytogenetic findings in the bone marrow. The platelet level in patients diagnosed with CNL is usually normal or low, but thrombocytosis has been reported in some patients with CNL (2, 5). Significant organomegaly is also unlikely to occur in myelodysplastic syndrome. There have been reports of raised neutrophil counts in association with plasma cell dyscrasias, such as monoclonal gammopathy of unknown significance or multiple myeloma (6) (7) (8) . However, there was no evidence of paraproteinemia in our patient.
There have been a few descriptions of an association between CNL meeting the current WHO diagnostic criterion and the JAK2 V617F mutation, and this has been confirmed in some cases of CNL. Some reports suggested a possible relationship between the presence of a JAK2 mutation and long survival in patients with CNL (9-11). However, one report indicated that JAK2 V617F-positive CNL may be an aggressive disease entity (12). Zhang et al. (13) published the case of a patient with a JAK2 V617F mutation who was treated with interferon alpha-2b and achieved a good prognosis; the authors also reviewed CNL with JAK2 V617F mutations in the literature and found five cases (including theirs). Although detailed information was not provided for one of the cases, two patients treated with HU and their case treated with interferon survived, another one who received a bone marrow transplant died. Although the association between the prognosis and the presence of a JAK2 V617F mutation remains unclear in CNL, the present JAK2 V617F-positive case with CNL was stable for about two years until the recent occurrence of NS. Notably, the patient's NS rapidly and completely recovered, and her CNL remains stable with HU therapy, which may indicate benign progress. Recently, Said et al. (14) reported that MPNrelated glomerulopathy was a late complication of neoplasms with a generally poor renal outcome. Hass et al. (15) questioned whether earlier recognition of MPN-related glomerulopathy might have resulted in better renal outcomes, yet evidence from other primary and secondary glomerular diseases suggests that this is not unreasonable. The present case did not exhibit either globally sclerotic glomeruli or moderate/severe tubulointerstitial scarring, which is different from the patients described by Said et al. (14) .
Glomerulonephropathies (GNs) have long been linked to hematologic malignancies, and their association is continually expanding. Hematologic malignancies can lead to glomerular insults, such as matrix/abnormal protein accumulation, proliferative GN/hypercellular glomeruli, and podocytopathy (15) . Plasma-cell dyscrasias, podocyte injury caused by neoplastic cells, and released cytokines/permeability factors might be causes of GN, but the exact mechanism is still unclear (16, 17) . As recently reported by Said et al. (14) , the histologic features of MPN-related glomerulopathy include mesangial sclerosis and hypercellularity, segmental sclerosis, and intracapillary hematopoietic cells. MPN-related glomerulopathy develops with a variety of MPNs, but primary myelo-fibrosis is by far the most common. Primary fibrosis leads to the deposition of fibrous tissue and extramedullary hematopoiesis. Our patient's bone marrow did not show evidence of myelofibrosis, but her spleen tissue did show extramedullary hematopoiesis. To our knowledge, our patient represents the first case report of NS related to CNL. We diagnosed NS related to CNL based on two important findings. Firstly, a JAK2 V617F mutation was found in her peripheral blood and kidney tissue. Secondly, her CNL symptoms remitted, her urine protein levels significantly improved, and her serum albumin returned to normal level following HU and interferon without the addition of an immunosuppressant. Patients with idiopathic FSGS, particularly those with severe proteinuria, as in the current case, are often slowly and poorly responsive to immunosuppressive therapy (18) . Conversely, an improvement of the NS secondary to FSGS in association with hematological malignancies appears to be prompt and significant (19, 20) .
The optimal therapy for CNL remains to be defined. To date, the treatment for CNL has largely consisted of cytoreductive agents, such as HU. This first-line agent achieves a clinical response in terms of decreased leukocytosis and/or splenomegaly (21) . Splenectomy or splenic irradiation has been found to be effective in reducing symptomatic splenomegaly, but this may aggravate neutrophilia (22) . Other treatments, such as alpha-interferon, have been used with some success to reduce the tumor burden without suppressing normal hematopoeisis (3) . In view of the aggressive nature and possible leukemia transformation from CNL, bone marrow transplants should be considered for younger patients with a suitable donor. In our patient, the early stage treatment was HU to control white blood cell levels, and interferon was administered three months later to control white blood cell proliferation.
In summary, this is the first known case of a 41-year-old woman presenting with NS and hyperleukocytosis who was ultimately diagnosed with CNL. In this case, FSGS-type NS was confirmed by kidney biopsy. The positivity of JAK2 V617F in her peripheral blood and kidney tissue and the short-term duration of the patient's NS indicated that it was related to CNL. Bertelli et al. (23) reported that neutrophilia can induce a ten-fold increase of oxygen radical production in children with idiopathic NS, and this change correlates with the degree of proteinuria. Performing a splenectomy could aggravate neutrophilia and thrombocytosis, and severe neutrophilia may thus be a reason for the late appearance of NS, which is a contra-indication for a splenectomy.
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